Surface plasmon resonance biosensors for simultaneous monitoring of amyloid-beta oligomers and fibrils and screening of select modulators

Micromotor-based electrochemical immunoassays for reliable determination of amyloid-β (1-42) in Alzheimer's diagnosed clinical samples

Alzheimer's disease (AD), in addition to being the most common cause of dementia, is very difficult to diagnose, with the 42-amino acid form of Aβ (Aβ-42) being one of the main biomarkers used for this purpose. Despite the enormous efforts made in recent years, the technologies available to determine Aβ-42 in human samples require sophisticated instrumentation, present high complexity, are sample and time-consuming, and are costly, highlighting the urgent need not only to develop new tools to overcome these limitations but to provide an early detection and treatment window for AD, which is a top-challenge. In recent years, micromotor (MM) technology has proven to add a new dimension to clinical biosensing, enabling ultrasensitive detections in short times and microscale environments. To this end, here an electrochemical immunoassay based on polypyrrole (PPy)/nickel (Ni)/platinum nanoparticles (PtNPs) MM is proposed in a pioneering manner for the determination of Aβ-42 in left prefrontal cortex brain tissue, cerebrospinal fluid, and plasma samples from patients with AD. MM combines the high binding capacity of their immunorecognition external layer with self-propulsion through the catalytic generation of oxygen bubbles in the internal layer due to decomposition of hydrogen peroxide as fuel, allowing rapid bio-detection (15 min) of Aβ-42 with excellent selectivity and sensitivity (LOD = 0.06 ng/mL). The application of this disruptive technology to the analysis of just 25 μL of the three types of clinical samples provides values concordant with the clinical values reported, thus confirming the potential of the MM approach to assist in the reliable, simple, fast, and affordable diagnosis of AD by determining Aβ-42.

Aggregation-induced electrochemiluminescence enhancement of Ag-MOG for amyloid β 42 sensing

This study aimed to introduce an immunosensor for measuring amyloid β 42 (Aβ42) levels by aggregation-induced enhanced electrochemiluminescence (ECL). Metal-organic gels (MOGs) are novel soft materials with advantages such as high gel stability, good light-emitting properties, and easy preparation. This study used silver nanoparticle metal-organic gel (Ag-MOG) as a substrate to connect Aβ42-Ab2 and the cathodoluminescent probe. Potassium persulfate was used as a co-reactant that could emit a high ECL signal. CuS@Au had the benefits of a relatively large surface area with excellent carrier function; therefore, it was used as a substrate to load a large amount of Aβ42-Ab1, significantly improving the immunosensor sensitivity. The ECL intensity of Aβ42 was linear in the range of 0.01 pg/mL to 250 ng/mL with a detection limit of 2.2 fg/mL (S/N = 3) under optimized detection conditions. This ECL immunosensor has been successfully applied to detect Aβ42 in human serum with the advantages of excellent stability and high selectivity. This method not only expands the potential applications of ECL immunosensors based on biological testing and clinical diagnosis but also provides a viable approach to basic clinical testing.

Sensitive dual-mode sensing platform for Amyloid β detection: Combining dual Z-scheme heterojunction enhanced photoelectrochemistry analysis and dual-wavelength ratiometric electrochemiluminescence strategy

As a tumor biomarker, the accumulation of amyloid β oligomers (Aβo) in the brain has been suggested as a key feature in the pathogenesis and progression of Alzheimer's disease (AD). In this work, we designed a novel photoelectrochemical (PEC) and electrochemiluminescence resonance energy transfer (ECL-RET) dual-mode biosensor to achieve ultra-sensitive detection of Aβo. Specifically, the electrode surface modified Carbon Dots (C Dots) and the electrodeposited polyaniline (PANI) film formed a Z-scheme heterojunction reversing the photocurrent signal, and then the Aβo specific recognition peptide was attached to the surface via amide bonding between the amino group of PANI and carbonyl group of peptide. After that, in the presence of CdTe labeled specific recognition aptamer for Aβ (CdTe-Apt), Aβo was captured to construct a sandwich-type biosensor and exhibited a significantly enhanced cathodic photocurrent response because the formed dual Z-scheme heterojunction promoted charge separation efficiency. Interestingly, the proposed biosensor also caused a ratiometric change in the ECL intensity at 555 nm and 640 nm. Therefore, the developed biosensor achieved dual-mode detection of Aβo, where the PEC detection range of Aβo was from 10 fM to 0.1 μM (with a detection limit of 4.27 fM) and the ECL method provided a linear detection range of 10 fM to 10 nM (with a detection limit of 6.41 fM). The stability and reliability of the experimental results indicate that this has been a promising biosensing pattern and could be extended to the analysis of other biomarkers.

Synthesis of a novel carboxybetaine copolymer with different spacer lengths and inhibition of nonspecific protein adsorption on its polymer film

Herein, we designed and synthesized a thermally stable carboxybetaine copolymer with a one- or three-carbon spacer between ammonium and carboxylate groups (CBMA1 and CBMA3) to create an anti-nonspecific adsorption surface with the ability to immobilize antibodies. A series of controlled poly(N,N-dimethylaminoethyl methacrylate) was successfully prepared using reversible addition-fragmentation chain-transfer (RAFT) polymerization and was derived to carboxybetaine copolymers of poly(CBMA1-co-CBMA3) [P(CBMA1/CBMA3)] with various CBMA1 contents, including the homopolymers of CBMA1 and CBMA3. Thermal stability of the carboxybetaine (co)polymers was higher than that of the carboxybetaine polymer with a two-carbon spacer (PCBMA2). Further, we also evaluated nonspecific protein adsorption in fetal bovine serum and antibody immobilization on the substrate coated with P(CBMA1/CBMA3) copolymers using surface plasmon resonance (SPR) analysis. As the CBMA1 content increased, nonspecific protein adsorption on the P(CBMA1/CBMA3) copolymer surface decreased. Similarly, the immobilization amount of the antibody decreased as the CBMA1 content increased. However, the figure of merit (FOM), defined as the ratio of the amount of antibody immobilization to that of nonspecific protein adsorption, depended on the CBMA3 content; FOM was higher when the CBMA3 content was 20-40% than those of CBMA1 and CBMA3 homopolymers. These findings will help enhance the sensitivity of the analysis using molecular interaction measurement devices, such as SPR and quartz crystal microbalance.

Review: Investigating the aggregation of amyloid beta with surface plasmon resonance: Do different approaches yield different results?

Aggregation of amyloid beta into amyloid plaques in the brain is a hallmark characteristic of Alzheimer's disease. Therapeutics aimed at preventing or retarding amyloid formation often rely on detailed characterization of the underlying mechanism and kinetics of protein aggregation. Surface plasmon resonance (SPR) spectroscopy is a robust technique used to determine binding affinity and kinetics of biomolecular interactions. This approach has been used to characterize the mechanism of aggregation of amyloid beta but there are multiple pitfalls that need to be addressed when working with this and other amyloidogenic proteins. The choice of method for analyte preparation and ligand immobilization to a sensor chip can lead to different theoretical and practical implications in terms of the mathematical modelling of binding data, different mechanisms of binding and the presence of different interacting species. This review examines preparation methods for SPR characterisation of the aggregation of amyloid beta and their influence on the findings derived from such studies.

Electrocatalysis of Copper Sulfide Nanoparticle-Engineered Covalent Organic Frameworks for Ratiometric Electrochemical Detection of Amyloid-β Oligomer

Amyloid-β oligomer (AβO) is widely regarded as a reliable biomarker for the early diagnosis of Alzheimer's disease (AD). In this study, a signal on-off ratiometric electrochemical immunosensor has been developed for ultrasensitive detection of AβO. To achieve the dual-signal ratiometric strategy, ultrasmall copper sulfide nanoparticle-engineered covalent organic framework hybrid nanocomposites (CuS@COFs) were utilized as excellent electrocatalysts toward hydroquinone (HQ) oxidation to produce detectable signals. Meanwhile, electroactive thionine (Thi) and Aβ antibody-modified gold nanoparticles (Thi-AuNPs-Ab bioconjugates) were designed as another electrochemical indicator. Based on these two signals, an ultrasensitive sandwich-like electrochemical immunosensor was established for AβO detection. The introduction of AβO resulted in a remarkable decline in the electrochemical signal of HQ but an increase in the signal of Thi. Under optimum conditions, the ratios between the double signals (I_Thi/I_HQ) showed a proportional linear relationship with the AβO concentration (1 pM-1 μM) with a low detection limit of 0.4 pM (S/N = 3), and the biosensor was able to determine the content of AβO in real cerebrospinal fluid samples with satisfactory results. The ratiometric strategy proposed in our study offers a sensitive and efficient approach for early diagnosis of AD, and this work will promote the further applications of engineered COFs in electrochemical sensors.

Potentiometric Biosensor Based on Artificial Antibodies for an Alzheimer Biomarker Detection

This paper presents a potentiometric biosensor for the detection of amyloid β-42 (Aβ-42) in point-of-care analysis. This approach is based on the molecular imprint polymer (MIP) technique, which uses covalently immobilised Aβ-42 to create specific detection cavities on the surface of single-walled carbon nanotubes (SWCNTs). The biosensor was prepared by binding Aβ-42 to the SWCNT surface and then imprinting it by adding acrylamide (monomer), N,N’-methylene-bis-acrylamide (crosslinker) and ammonium persulphate (initiator). The target peptide was removed from the polymer matrix by the proteolytic action of an enzyme (proteinase K). The presence of imprinting sites was confirmed by comparing a MIP-modified surface with a negative control (NIP) consisting of a similar material where the target molecule had been removed from the process. The ability of the sensing material to rebind Aβ-42 was demonstrated by incorporating the MIP material as an electroactive compound in a PVC/plasticiser mixture applied to a solid conductive support of graphite. All steps of the synthesis of the imprinted materials were followed by Raman spectroscopy and Fourier transform infrared spectroscopy (FTIR). The analytical performance was evaluated by potentiometric transduction, and the MIP material showed cationic slopes of 75 mV-decade−1 in buffer pH 8.0 and a detection limit of 0.72 μg/mL. Overall, potentiometric transduction confirmed that the sensor can discriminate Aβ-42 in the presence of other biomolecules in the same solution.

Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?

Discovered more than a century ago, Alzheimer's disease (AD) is not only still present in our societies but has also become the most common dementia, with 50 million people worldwide affected by the disease. This number is expected to double in the next generation, and no cure is currently available to slow down or stop the disease progression. Recently, some advances were made due to the approval of the aducanumab treatment by the American Food and Drug Administration. The etiology of this human-specific disease remains poorly understood, and the mechanisms of its development have not been completely clarified. Several hypotheses concerning the molecular mechanisms of AD have been proposed, but the existing studies focus primarily on the two main markers of the disease: the amyloid β peptides, whose aggregation in the brain generates amyloid plaques, and the abnormally phosphorylated tau proteins, which are responsible for neurofibrillary tangles. These protein aggregates induce neuroinflammation and neurodegeneration, which, in turn, lead to cognitive and behavioral deficits. The challenge is, therefore, to create models that best reproduce this pathology. This review aims at gathering the different existing AD models developed in vitro, in cellulo, and in vivo. Many models have already been set up, but it is necessary to identify the most relevant ones for our investigations. The purpose of the review is to help researchers to identify the most pertinent disease models, from the most often used to the most recently generated and from simple to complex, explaining their specificities and giving concrete examples.

A Multi-Chamber Paper-Based Platform for the Detection of Amyloid β Oligomers 42 via Copper-Enhanced Gold Immunoblotting

The early diagnosis of Alzheimer's disease (AD) remains a challenge for medical scientists worldwide, leading to a number of research efforts that focus on biosensor development for AD biomarkers. However, the application of these complicated biosensors is limited in medical diagnosis, due to the difficulties in robust sensing platform development, high costs, and the necessity for technical professionals. We successfully developed a robust straightforward manufacturing process for the fabrication of multi-chamber paper devices using the wax printing method and exploited it to detect amyloid beta 42 oligomers (AβO42, a significant biomarker of AD) using copper-enhanced gold nanoprobe colorimetric immunoblotting. Small hydrophilic reaction chambers could concentrate the target sample to the desired size to improve the sensing performance. The copper-enhanced gold nanoprobe immunoblot using the designed multi-chamber platform exhibited a highly sensitive performance with a limit of detection of 320 pg/mL by the naked eye and 23.7 pg/mL by a smartphone camera. This process from sensing manufacture to sensing conduction is simple to perform whenever medical technicians require time- and cost-savings, without complicated instruments or the need for technical professionals, making it feasible to serve as a diagnostic tool worldwide for the early monitoring of AD and scalable devices for the sensing application of various biomarkers in clinical settings.

Molybdenum disulfide nanosheets-based fluorescent "off-to-on" probe for targeted monitoring and inhibition of β-amyloid oligomers

A novel and simple "off-to-on" fluorescent sensing platform for β-amyloid oligomers (Aβo) was developed based on dye (FAM)-labeled single-strand DNA (FAM-ssDNA)-conjugated molybdenum disulfide nanosheets (MoS2 NSs). Due to strong adsorption of ss-DNA to the surface of MoS2 NSs, the fluorescence of FAM was quenched remarkably, leading to a fluorescent "off" state. However, in the presence of Aβo, a hybrid structure between Aβo and FAM-ssDNA resulted in the dissociation of FAM-ssDNA from MoS2 NSs and an obvious fluorescence recovery transformed the fluorescence to an "on" state. The developed fluorescence sensing assay showed a good linear relationship toward Aβo ranging from 0.01 to 20 μM (R2 = 0.994) with a satisfactory detection limit of 3.1 nM. Practical samples of hippocampus and cortex tissues from APP/PS1 double transgenic AD mice were applied to demonstrate feasibility of the assay. Moreover, we found that similar to MoS2 nanoparticles, MoS2 NSs possessed therapeutic effects on Alzheimer's disease (AD) by inhibiting Aβ aggregations and degrading the previously formed Aβ fibrils. Collectively, the high sensitivity, specificity, and good biocompatibility along with an efficient anti-aggregation ability, the presented fluorescent strategy with MoS2 NSs demonstrated their promising potential for future AD-related research.

Alzheimer's Disease Determination by a Dual Probe on Gold Nanourchins and Nanohorn Hybrids

Background

Alzheimer’s disease (AD) is a neurodegenerative chronic disorder that causes dementia and problems in thinking, cognitive impairment and behavioral changes. Amyloid-beta (Aβ) is a peptide involved in AD progression, and a high level of Aβ is highly correlated with severe AD. Identifying and quantifying Aβ levels helps in the early treatment of AD and reduces the factors associated with AD.

Materials and Methods

This research introduced a dual probe detection system involving aptamers and antibodies to identify Aβ. Aptamers and antibodies were attached to the gold (Au) urchin and hybrid on the carbon nanohorn-modified surface. The nanohorn was immobilized on the sensor surface by using an amine linker, and then a Au urchin dual probe was immobilized.

Results

This dual probe-modified surface enhanced the current flow during Aβ detection compared with the surface with antibody as the probe. This dual probe interacted with higher numbers of Aβ peptides and reached the detection limit at 10 fM with R²=0.992. Furthermore, control experiments with nonimmune antibodies, complementary aptamer sequences and control proteins did not display the current responses, indicating the specific detection of Aβ.

Conclusion

Aβ-spiked artificial cerebrospinal fluid showed a similar response to current changes, confirming the selective identification of Aβ.

Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease

This review highlights current developments, challenges, and future directions for the use of invasive and noninvasive biosample-based small biosensors for early diagnosis of Alzheimer's disease (AD) with biomarkers to incite a conceptual idea from a broad number of readers in this field. We provide the most promising concept about biosensors on the basis of detection scale (from femto to micro) using invasive and noninvasive biosamples such as cerebrospinal fluid (CSF), blood, urine, sweat, and tear. It also summarizes sensor types and detailed analyzing techniques for ultrasensitive detection of multiple target biomarkers (i.e., amyloid beta (Aβ) peptide, tau protein, Acetylcholine (Ach), microRNA137, etc.) of AD in terms of detection ranges and limit of detections (LODs). As the most significant disadvantage of CSF and blood-based detection of AD is associated with the invasiveness of sample collection which limits future strategy with home-based early screening of AD, we extensively reviewed the future trend of new noninvasive detection techniques (such as optical screening and bio-imaging process). To overcome the limitation of non-invasive biosamples with low concentrations of AD biomarkers, current efforts to enhance the sensitivity of biosensors and discover new types of biomarkers using non-invasive body fluids are presented. We also introduced future trends facing an infection point in early diagnosis of AD with simultaneous emergence of addressable innovative technologies.

Graphene oxide-gold nanoparticle-aptamer complexed probe for detecting amyloid beta oligomer by ELISA-based immunoassay

Highly sensitive and easy detection method for Alzheimer's disease (AD) with a suitable biomarker is mandatory for preventing the factors resulting from AD. This research reports a modified ELISA with graphene for the detection of AD biomarker amyloid beta (Aβ) oligomer. Gold nanoparticle (AuNP) conjugated aptamer was used as the capture probe and attached on ELISA-graphene oxide surface through the amine linker. Antibody was used as the detection molecule to reach the maximum detection of Aβ oligomer. Suitable level of APTMS (2%), size of AuNP (30 nm) and aptamer concentration (2 μM) were optimized. This sandwich pattern of aptamer-Aβ oligomer-antibody helps to reach the detection at 50 pM on the optimized ELISA surface and the control experiments in the absence of Aβ oligomer or anti-Aβ oligomer antibody did not show the significant optical detection at 492 nm, indicting the specific detection. Further, Aβ oligomer spiked artificial cerebrospinal fluid did not interfere the detection of Aβ oligomer, confirming the selective detection. This new and modified ELISA surface helps to reach the lower detection of Aβ oligomer and diagnose AD.

Immunosensor incorporating half-antibody fragment for electrochemical monitoring of amyloid-β fibrils in artificial blood plasma

In this report, an electrochemical immunosensor for the selective and sensitive monitoring of Aβ_1-42 fibrils is presented. The sensing platform was prepared by the formation of a 4,4'-thiobisbenzenethiol (TBBT) self-assembled monolayer on a clean gold surface followed by the covalent entrapment of gold nanoparticles (AuNPs). The half-antibody fragments of the Anti-Amyloid Fibrils antibody were immobilized on AuNPs via S-Au covalent bonds. Each step of immunosensor fabrication was characterized with cyclic voltammetry and electrochemical impedance spectroscopy. The biosensor was successfully used for the sensing of Aβ_1-42 fibrils in both phosphate saline buffer (PBS) and artificial blood plasma (ABP). The immunosensor sensitivity estimated based on calibration slopes was better in the presence of APP in the comparison to PBS. The LOD values obtained for both measuring media were of 0.6 pM level. The moderate response towards Aβ_1-42 oligomers demonstrated the immunosensor selectivity.

Au nano-urchins enabled localized surface plasmon resonance sensing of beta amyloid fibrillation

Early stage detection of neurodegenerative diseases such as Alzheimer's disease (AD) is of utmost importance, as it has become one of the leading causes of death of millions of people. The gradual intellectual decline in AD patients is an outcome of fibrillation of amyloid beta 1-42 (Aβ1-42) peptides in the brain. In this paper, we present localized surface plasmon resonance (LSPR) based sensing of Aβ1-42 fibrillation using Au nano-urchins. Strongly localized field confinement at the spiky nanostructures of nano-urchin surfaces enables them to detect very low concentrations of Aβ1-42. In addition, the LSPR peak of Au nano-urchins, which is very sensitive to ambient conditions, shows significant responses at different fibrillation stages of Aβ1-42. Reduction in LSPR peak intensity with an increase in the fibrillation is chosen as the sensing parameter here. This paper in this context provides LSPR based highly sensitive, label-free and real-time sensing of Aβ1-42 fibrillation that is highly advantageous compared to the existing techniques which require binding additives or fluorescent biomarkers.

Exploring Interactions of Aptamers with Aβ40 Amyloid Aggregates and Its Application: Detection of Amyloid Aggregates

The exhaustive investigating interactions between recognition probes and amyloid aggregates, especially simultaneous recognition events, are challenging and crucial for the design of biosensing probes and further diagnosis of amyloid diseases. In the present work, the interactions of aptamers (Apts) with β-amyloid (Aβ) aggregates were explored thoroughly by single-molecule force spectroscopy (SMFS). Indeed, it was found that the interaction of aptamer1 (Apt1)-amyloid aggregates was different from that of aptamer2 (Apt2)-Aβ₄₀ aggregates at the single-molecule level. Especially, the interaction force of Apt1-Aβ₄₀ fibril showed a double distinguishing Gaussian fitting. The only unimodal distribution of the force histogram was displayed for the interactions of Apt2-Aβ₄₀ oligomer, Apt2-Aβ₄₀ fibril, and Apt1-Aβ₄₀ oligomer. More intriguingly, two Apts could bind to amyloid aggregates simultaneously. With the assistance of two Apts recognition, a novel sensitive dual Apt-based surface plasmon resonance (SPR) sensor using Au nanoparticles (AuNPs) was developed for quantifying Aβ₄₀ aggregates. The dual Apt-based SPR sensor not only avoided the limitation of steric hindrance and epitope but also employed simple operation as well as inexpensive recognition probes. A detection limit as low as 0.2 pM for Aβ₄₀ oligomer and 0.05 pM for Aβ₄₀ fibril could be achieved. Moreover, the established sensor could be successfully applied to detect Aβ₄₀ aggregates in artificial cerebrospinal fluid (CSF) and undiluted real CSF. This work could provide a strategy to monitor a simultaneous recognition event using SMFS and broaden the application of Apts in the diagnosis of neurodegenerative diseases.

A simple aptasensor for Aβ40 oligomers based on tunable mismatched base pairs of dsDNA and graphene oxide

β-amyloid 1-40 oligomers (Aβ₄₀O) is considered to be one of the important biomarkers for the diagnosis and treatment of Alzheimer's disease (AD). To explore a method with excellent performance is favorable for measuring the low concentration of Aβ₄₀O in AD patients. Here, we developed a simple and fast method with a double stranded DNA (dsDNA)/graphene oxide (GO) based sensor, which was a fluorescent probe for a highly sensitive detection of Aβ₄₀O down to 0.1 nM with a linear detectable range from 0.1 nM to 40 nM. The proposed sensor effectively reduced non-specific adsorption and improved the specificity of detection because of the covalent conjugation of a binding DNA (bDNA) containing Aβ₄₀O-targeting aptamer (Apt_Aβ) onto GO surface, as well as the optimization of the number of mismatch base pairs of dsDNA. Moreover, AD patients and healthy persons were distinguished by this present method. All advantages of this method are exactly what the clinical detection of AD biomarkers need. This novel aptasensor might pave a way towards the early diagnosis of AD.

A label-free and signal-on electrochemiluminescence strategy for sensitive amyloid-beta assay

Development of a simple, cost-effective and sensitive biosensing strategy is highly desirable to advance the applications in Alzheimer's disease diagnosis. In this paper, we present a simple, label-free and signal-on electrochemiluminescence (ECL) aptasensor for the detection of amyloid-beta (Aβ) peptide using luminol as ECL emitter and in-situ generated reactive oxygen species (ROS) as coreactant via catalytic reaction between Cu²⁺-Aβ and the dissolved O₂ in the presence of ascorbic acid (AA). Aβ₁₆, the binding site of Cu²⁺ in the monomeric full-length Aβ, was used as a model in present study. As a result, this signal-on ECL aptasensor has exhibited favorable analytical performance for Aβ₁₆ monomer with a linear range of 1.0 × 10^-13 mol/L-1.0 × 10^-8 mol/L and a limit of detection of 3.5 × 10^-14 mol/L (S/N=3). Furthermore, the proposed biosensor was also able to detect the full length Aβ₄₀ not only in the phosphate buffer saline (PBS) solution but also in human serum. The presented biosensor represents a promising, simple, turn-on and label-free diagnostic tool for blood analysis.

Highly sensitive aptasensor based on interferometric reflectance spectroscopy for the determination of amyloid β as an Alzheimer's disease biomarkers using nanoporous anodic alumina

It is well known that Alzheimer's disease is one of the global challenges for the 21st century. Therefore, it is urgent to develop a reliable biosensor for the detection of this disease. Here in, we have developed for the first time, an aptasensor based on interferometric reflectance spectroscopy (IRS) for the determination of amyloid β (Aβ) oligomers that is an Alzheimer's disease biomarker. For this purpose, the nanoporous anodic alumina (NAA) was first fabricated. After that, the pore walls of the NAA were modified with (3-aminopropyl) trimethoxysilane (NAA-NH₂). The amino-terminal aptamers probe were then attached to the pore walls of the NAA-NH₂ by using glutaraldehyde (GA) as the cross-linking agent. Subsequently, methylene blue (MB) was immobilized into the aptamer as the photo-probe, generating the MB/G-quadruplex complex. Since MB has a high absorption coefficient, the intensity of the reflected white light to the charge-coupled device (CCD) detector decreased. In the presence of the Aβ oligomers that have high affinity to the immobilized aptamer, the MB/quadruplex complex broke and MB washed away from the aptasensor. Therefore, the intensity of the reflected white light to the CCD detector increased. The increased signal intensity of the aptasensor has a logarithmic relationship with the concentration of Aβ oligomers. The proposed aptasensor exhibited a good response to the concentration of Aβ oligomers in the range of 0.5-50.0 μg × mL^-1. The experimental detection limit was of 0.02 μg × mL^-1 (at 3σ/S). The proposed optical aptasensor exhibited good selectivity, linear range, and stability.

Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease

The purpose of our article is to assess the current understanding of Indian spice, curcumin, against amyloid-β (Aβ)-induced toxicity in Alzheimer's disease (AD) pathogenesis. Natural products, such as ginger, curcumin, and gingko biloba have been used as diets and dietary supplements to treat human diseases, including cancer, cardiovascular, respiratory, infectious, diabetes, obesity, metabolic syndromes, and neurological disorders. Products derived from plants are known to have protective effects, including anti-inflammatory, antioxidant, anti-arthritis, pro-healing, and boosting memory cognitive functions. In the last decade, several groups have designed and synthesized curcumin and its derivatives and extensively tested using cell and mouse models of AD. Recent research on Aβ and curcumin has revealed that curcumin prevents Aβ aggregation and crosses the blood-brain barrier, reach brain cells, and protect neurons from various toxic insults of aging and Aβ in humans. Recent research has also reported that curcumin ameliorates cognitive decline and improves synaptic functions in mouse models of AD. Further, recent groups have initiated studies on elderly individuals and patients with AD and the outcome of these studies is currently being assessed. This article highlights the beneficial effects of curcumin on AD. This article also critically assesses the current limitations of curcumin's bioavailability and urgent need for new formulations to increase its brain levels to treat patients with AD.

TMPyP Inhibits Amyloid-β Aggregation and Alleviates Amyloid-Induced Cytotoxicity

The aggregation or misfolding of amyloid-β (Aβ) is a major pathological hallmark of Alzheimer's disease (AD). The regulation of Aβ aggregation is thought to be an effective strategy for AD treatment. The capability of a water-soluble porphyrin, 5,10,15,20-tetrakis(N-methyl-4-pyridyl)porphyrin (TMPyP), to inhibit Aβ aggregation and to lower Aβ-induced toxicity was demonstrated. As evidenced by surface plasmon resonance and circular dichroism, TMPyP can not only disrupt Aβ aggregation but also disassemble the preformed Aβ aggregates. The atomic force microscopy imaging proves that TMPyP inhibits the formation of both oligomers and fibrils. Molecular dynamic simulations provide an insight into the interaction between TMPyP and Aβ at the molecular level. The half-maximal inhibitory concentrations of TMPyP acting on the oligomers and fibrils were determined to be 0.6 and 0.43 μM, respectively. As a member of porphyrin family, TMPyP is of rather low cytotoxicity, and the cytotoxicity of the Aβ aggregates was also relieved upon coincubation with TMPyP. The excellent performance of TMPyP thus makes it a potential drug candidate for AD therapy.

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

Soluble beta-amyloid (Aβ) oligomer is believed to be the most important toxic species in the brain of Alzheimer’s disease (AD) patients. Thus, it is critical to develop a simple method for the selective detection of Aβ oligomer with low cost and high sensitivity. In this paper, we report an electrochemical method for the detection of Aβ oligomer with a peptide as the bioreceptor and silver nanoparticle (AgNP) aggregates as the redox reporters. This strategy is based on the conversion of AgNP-based colorimetric assay into electrochemical analysis. Specifically, the peptide immobilized on the electrode surface and presented in solution triggered together the in situ formation of AgNP aggregates, which produced a well-defined electrochemical signal. However, the specific binding of Aβ oligomer to the immobilized peptide prevented the in situ assembly of AgNPs. As a result, a poor electrochemical signal was observed. The detection limit of the method was found to be 6 pM. Furthermore, the amenability of this method for the analysis of Aβ oligomer in serum and artificial cerebrospinal fluid (aCSF) samples was demonstrated.

Detection of Aβ oligomers based on magnetic-field-assisted separation of aptamer-functionalized Fe3O4 magnetic nanoparticles and BaYF5:Yb,Er nanoparticles as upconversion fluorescence labels

A sensitive and stable bioassay for the detection of Aβ oligomer (Aβo), a potentially promising candidate biomarker for Alzheimer's disease (AD) diagnosis, was developed using Fe₃O₄ magnetic nanoparticles (MNPs) as the recognition and concentration elements and BaYF₅:Yb,Er upconversion nanoparticles (UCNPs) as highly sensitive labels, conjugated with the Aβo aptamer (DNA1) and the complementary oligonucleotide of the Aβo aptamer (DNA2), respectively. The DNA1 hybridized with DNA2 to form the duplex structure on the surface of the MNPs/UCNPs nanocomposites probe. When the target Aβo was introduced, the aptamer DNA1 preferentially bound with Aβo and caused the dissociation of some complementary DNA2, liberating some UCNP-labeled complementary DNA2 and leading to a decreased upconversion fluorescent intensity on the surface of MNPs. The decreased fluorescence intensity of UCNPs was related to the concentration of Aβo in the range of 0.2-15nM with a detection limit of 36 pM. The developed method then was successfully applied to measure Aβo in artificial cerebrospinal fluid. Benefiting from the magnetic separation and concentration effect of MNPs, the high sensitivity of UCNPs, as well as the selectivity and stability of the aptamer, the present strategy offered valuable information related to early diagnosis of AD process.

Fabrication of an antibody-aptamer sandwich assay for electrochemical evaluation of levels of β-amyloid oligomers

Amyloid β-peptide (Aβ) in its oligomeric form is often considered as the most toxic species in Alzheimer's disease (AD), and thus Aβ oligomer is a potentially promising candidate biomarker for AD diagnosis. The development of a sensitive and reliable method for monitoring the Aβ oligomer levels in body fluids is an urgent requirement in order to predict the severity and progression at early or preclinical stages of AD. Here, we show a proof of concept for a sensitive and specific detection of Aβ oligomers by an antibody-aptamer sandwich assay. The antibodies of Aβ oligomers and a nanocomposite of gold nanoparticles with aptamer and thionine (aptamer-Au-Th) were used as the recognition element and the detection probe for specifically binding to Aβ oligomers, respectively. The electrochemical signal of Th reduction could provide measurable electrochemical signals, and a low limit of detection (100 pM) was achieved due to the signal amplification by high loading of Th on the gold nanoparticles. The feasibility of the assay was verified by test of Aβ oligomers in artificial cerebrospinal fluid. The proposed strategy presents valuable information related to early diagnosis of AD process.